Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 12% of the time (145 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-05-25. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Design: crossover (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports with a death: 52.5% (raises risk) · Drug's FDA history
• Phase: 1 (lowers risk) · Design
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: to determineplacebo controlledintravenousblind placebosafe
  Phrases that lowered it: safety ofdrugacidthe studymoderate
• Sponsor's past termination rate: 5% (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Drug's FAERS reports marked serious: 96.1% (raises risk) · Drug's FDA history
• Collaborators: 2 (lowers risk) · Design
• Sponsor's past trials: 60 (lowers risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area
• Drug's FAERS reports before start: 7160 (raises risk) · Drug's FDA history
• Blinding: double (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 14 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid NCT04411914 · started 2020 · scored riskier than 20% of active trials completed
• Open Label Pharmaco- Magnetic Resonance Spectrography (MRS) Study of Clavulanic Acid NCT03986762 · started 2019 · scored riskier than 30% of active trials completed
• Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD) NCT03242928 · started 2017 · scored riskier than 35% of active trials completed
• Behavioral and Physiological Effects of Cocaine in Cocaine-dependent Participants Treated With Levodopa in Combination With Carbidopa and Entacapone (LCE) NCT01437293 · started 2010 · scored riskier than 27% of active trials completed
• Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin NCT02393599 · started 2015 · scored riskier than 8% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.